pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›COLUMVI
drug
save

COLUMVI

updated 6mo ago
by Genentech Inc
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval12 co-mentions · 3 sources
  • drugglofitamab12 co-mentions · 3 sources
  • companyGenentech Inc6 co-mentions · 3 sources

all catalysts(0)

nothing on the calendar yet

News(7)

  • Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosion
    Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
    biospace · 1mo ago
  • Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
    Novartis is licensing an mRNA-based therapy designed to produce a CD3xCD19 T cell engager inside the body. Abogen Biosciences says the in vivo approach could reduce the likelihood of dangerous cyto…
    biospace · 1mo ago
  • ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
    When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
    fiercebiotech · 1mo ago
  • Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
    Genentech's agreement with Earendil Labs came the same day its parent company, Roche, inked a cardiometabolic and renal deal with Atavistik Bio for up to $2 billion.
    biospace · 1mo ago
  • Roche bets up to $1B to advance next-gen bispecifics with Dualitas
    The partners will focus R&D efforts on immunological and inflammatory conditions using Dualitas’ DualScreen Bispecific Discovery Engine platform.
    biospace · 2mo ago
  • Roche, Dualitas team up to find bispecific drugs for immune diseases
    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
    biopharma_dive · 2mo ago
  • Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
    Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
    fiercebiotech · 2mo ago
brand
COLUMVI
generic
GLOFITAMAB-GXBM
Data sources
ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?